Spinal Cord Stimulation for the Treatment of Major Depressive Disorder
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 20
- 试验地点
- 2
- 主要终点
- Montgomery Asberg Depression Rating Scale (MADRS) Score Change
研究概览
简要总结
This pilot clinical trial will evaluate the efficacy and safety of transcutaneous direct current stimulation (tsDCS) in major depressive disorder.
详细描述
This study aims to 1) determine the efficacy and safety of tsDCS in adult patients with major depressive disorder (MDD) and 2) investigate interoceptive awareness, somatic symptoms, autonomic and metabolic regulation as potential mediators of antidepressant response to tsDCS. We predict that 1) Active tsDCS treatment will result in a greater decrease in depressive symptom severity compared to Sham tsDCS in adult patients with MDD, 2) active tsDCS will be safe and well tolerated in adult patients with MDD and 3) change in interoceptive awareness, somatic symptoms, and autonomic and metabolic parameters will be associated with change in depressive symptom severity. To accomplish these aims, we will conduct an 8-week, double blinded, randomized, sham controlled, parallel group, pilot clinical trial study design. A total of 20 adult antidepressant-free MDD patients will be randomized to receive Active (n=10) or Sham (n=10) tsDCS protocols for 8 weeks in a 1:1 ratio. We will combine the use of a tsDCS device, psychometric instruments to diagnose MDD, and measures of depressive symptom severity, somatic symptoms, interoceptive awareness, autonomic function (blood pressure, heart rate), and potential metabolic markers as predictors of response.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
盲法说明
An independent operator (trained personnel from the research team) will prepare the tsDCS device parameters for each session, but will not participate in the rest of the assessments. Patients and raters will remain blinded to spinal stimulation protocol assigned to each participant throughout the study.
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
Montgomery Asberg Depression Rating Scale (MADRS) Score Change
时间窗: 8 weeks (or last available observation).
Difference in change from baseline to week 8 (or last available observation) in Montgomery Asberg Depression Rating Scale summed total scores scores between active and sham transcutaneous spinal direct current stimulation (tsDCS) groups. Scores range from 0 to 60, with higher scores indicating worse depressive symptom severity.
次要结局
- Number of Participants With Skin Redness(8 weeks)
- Clinical Global Impression-Improvement (CGI-I)(8 weeks)
- Montgomery Asberg Depression Rating Scale (MADRS) Sub-component Score (Item 2) Change(8 weeks)
- Patient Health Questionnaire-9 (PHQ-9) Score Change(8 weeks)
- Multidimensional Assessment of Interoceptive Awareness (MAIA) Score Change-Noticing Subscale(8 weeks)
- Binge Eating Scale (BES) Score Change(8 weeks)
- Four-Dimensional Symptom Questionnaire (4-DSQ)- Somatization Dimension Score Change(8 weeks)
- Heart Rate Score Change(8 weeks)
- Body Mass Index Change(8 weeks)
- Adiponectin Level Change(8 weeks)
- Leptin Level Change(8 weeks)
- Systolic Blood Pressure Score Change(8 weeks)
- Cortisol Level Change(8 weeks)
- Insulin Level Change(8 weeks)
- Fibroblast Growth Factor-21 (FGF-21) Level Change(8 weeks)
- Fatty Acid (LCn-3) Level Change(8 weeks)
研究者
Francisco Romo-Nava
Assistant Professor
University of Cincinnati